908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $16.1 million, up 23% year-over-year, driven by VipIR product demand and initial NIRLab contribution. The installed base grew 23% to 4,101 devices, including 198 devices placed in the quarter, and recurring revenue represented 31% of total revenue.
GAAP gross profit was $8.3 million with a 52% gross margin, while adjusted gross margin improved to 57%. Operating expenses were $21.2 million, including a sizeable noncash charge from the change in fair value of contingent consideration, leading to a net loss from continuing operations of $11.9 million. Adjusted EBITDA loss narrowed to $1.9 million, more than half the prior-year level.
The company held $101.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, with no debt, after using $13.5 million for the NIRLAB SA acquisition and receiving $3.5 million from an escrow release. Full-year 2026 revenue guidance was raised at the low end to $68.0–$70.0 million, representing 21%–25% growth versus 2025.
Christopher Brown filed a Form 144 indicating an intention to sell 100,000 shares of MASS common stock, originally acquired as founders shares, through Morgan Stanley Smith Barney LLC’s Executive Financial Services. The filing lists 37,813,621 MASS common shares outstanding and places the proposed sale value at $888,000.00, with prior sales in recent months executed under a Rule 10b5-1 trading plan.
908 Devices Inc. director Christopher D. Brown reported selling 20,000 shares of common stock on August 5, 2026 at a weighted average price of $8.49 per share, with trade prices ranging from $8.35 to $8.595. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025 and left Brown with 823,359 shares of common stock held directly.
AWM Investment Company, Inc., a ten percent owner of 908 Devices Inc., reported an indirect sale of 50,000 shares of Common Stock on August 4, 2026 at a weighted average price of $8.3553 per share. The shares are held through limited partnerships advised by AWM, which reported aggregate post-transaction holdings of 4,829,773 shares and disclaimed beneficial ownership except to the extent of its pecuniary interest.
908 Devices Inc. director Brandi C. Vann exercised Restricted Stock Units into 5,192 shares of Common Stock on August 1, 2026. Each RSU represents a contingent right to one share and vests in substantially equal annual installments over three years following August 1, 2025. After this transaction, Vann reported holdings of 10,385 RSUs and 5,192 shares of Common Stock, all held directly.
BlackRock, Inc. reports a passive ownership stake in 908 Devices Inc. common stock on a Schedule 13G. BlackRock reports beneficial ownership of 1,940,690 shares, representing 5.1% of the outstanding common stock. It has sole voting power over 1,917,820 shares and sole dispositive power over all 1,940,690 shares, with no shared voting or dispositive power reported. Various underlying clients and funds have rights to dividends or sale proceeds, but no single client holds more than five percent of 908 Devices’ outstanding common shares.
908 Devices Inc. issued 3,213,583 shares of common stock to satisfy the earnout consideration tied to its acquisition of RedWave Technology. These shares fulfill the company’s obligations under the April 29, 2024 Equity Purchase Agreement with CAM3 HoldCo, LLC and related sellers. The earnout was based on revenue from certain RedWave products and services over the period from May 1, 2024 through April 30, 2026, measured against a $37 million revenue threshold set in the agreement. With this issuance, the company states that its earnout obligations under the purchase agreement are now fully satisfied.
908 Devices Inc. President and CEO Kevin J. Knopp reported an open-market sale of 222 shares of common stock at a weighted average price of $9.07 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2025.
After this sale, Knopp directly holds 732,603 shares of common stock. Separately, 541,223 shares are held indirectly through The Kevin J. Knopp Irrevocable Trust of 2018, for which his brother-in-law, as trustee, has sole voting and dispositive control, while Knopp may be deemed a beneficial owner.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of common stock. On July 2, 2026, he sold 2,200 shares at a weighted average price of $9.02 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he directly holds 843,359 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported an open-market sale of 20,000 shares of common stock at a weighted average price of $8.84 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025.
Following this sale, Brown directly holds 845,559 shares of 908 Devices common stock. Because the sale was carried out pursuant to a Rule 10b5-1 plan, the timing reflects a preset trading arrangement rather than a discretionary decision based on recent company developments.